Clinical trials: Genitourinary Disease
Alport Syndrome
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
The purpose of the study is to learn about the safety and tolerability of setanaxib in subjects with Alport syndrome, when added to their standard of care treatment.
- Trial name
- NCT06274489
- Testing
- Setanaxib
- Where
- 17 sites in Austria, Czechia and 3 more
- Volunteers
- 20 people
- Sponsor
- Calliditas Therapeutics AB
End Stage Renal Disease
Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China
This is a multicenter, randomized, open-label study to compare QoL in subjects with end-stage renal disease (ESRD) requiring PD or conventional in-center HD treatment.
- Trial name
- NCT02378350
- Testing
- Hemodialysis treatment (no specific device is defined), Peritoneal Dialysis treatment (no specific drug is defined)
- Where
- 21 sites in China
- Volunteers
- 668 people
- Sponsor
- Vantive Health LLC
Renal Insufficiency
Afatinib in Subjects With Kidney Dysfunction
The primary objective of the current study is to investigate the influence of moderate to severe renal impairment on the pharmacokinetics and safety of a single dose afatinib in comparison to a control group with normal renal…
- Trial name
- NCT02096718
- Testing
- Afatinib healthy, Afatinib severe renally impaired, Afatinib moderate renally impaired
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease With High Proteinuria
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria
- Trial name
- ZODIAC (NCT06942910)
- Testing
- Zibotentan/Dapagliflozin, Dapagliflozin
- Where
- 14 sites in Russia
- Volunteers
- 224 people
- Sponsor
- AstraZeneca
Autosomal Dominant Polycystic Kidney Disease, ADPKD
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
Primary Objectives To assess the safety and tolerability of RGLS8429 To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) To…
- Conditions
- Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
- Trial name
- NCT05521191
- Testing
- RGLS8429
- Where
- 21 sites in United States
- Volunteers
- 68 people
- Sponsor
- Regulus Therapeutics Inc.
Ovarian Cancer
PTX-200 and Carboplatin in Ovarian Cancer
The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
- Trial name
- NCT01690468
- Testing
- Triciribine, Carboplatin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Prescient Therapeutics, Ltd.
Erectile Dysfunction
Phase 2a Trial to Investigate the Efficacy of LIB-01 in Treatment of Erectile Dysfunction
The goal of this clinical trial is to learn if the drug LIB-01 works to treat erectile dysfunction in male adults. It will also learn about the safety of the drug LIB-01.
- Trial name
- NCT06703840
- Testing
- LIB-01
- Where
- 6 sites in Denmark, Netherlands and 1 more
- Volunteers
- 156 people
- Sponsor
- Dicot AB
Infertility Unexplained
Modulation of Reproductive Microbiota by Ligilactobacillus Salivarius CECT5713
The objective of the project is to elucidate if the oral administration of Ligilactobacillus salivarius CECT5713 is capable of improving the rates of term pregnancies in couples with infertility problems of unknown cause.
- Trial name
- NCT06290518
- Testing
- Ligilactobacillus salivarius CECT5713
- Where
- 3 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Biosearch S.A.
Prostatic Neoplasms
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
The primary objective was to evaluate and compare the efficacy of androgen deprivation with or without docetaxel as determined by the median progression free survival (PFS) over the period of 18-month therapy and at least…
- Trial name
- Rising PSA (NCT00514917)
- Testing
- Docetaxel, Leuprolide, Bicalutamide
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Ovarian Cancer, Fallopian Tube Cancer
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03635489
- Testing
- Paclitaxel, Bevacizumab, Carboplatin
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Acute Heart Failure (AHF)
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard…
- Trial name
- RELAX-AHF-EU (NCT02064868)
- Testing
- Serelaxin, Standard of Care
- Where
- 357 sites in Austria, Belgium and 23 more
- Volunteers
- 2,666 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
Patients that completed any of the trials; CS27 (NCT00738673), CS28 (NCT00831233), CS30 (NCT00833248) or CS31 (NCT00884273) will be given the opportunity to receive monthly doses of degarelix until the drug is launched in their…
- Trial name
- NCT00967018
- Testing
- Degarelix
- Where
- 62 sites in Belgium, France and 5 more
- Volunteers
- 77 people
- Sponsor
- Ferring Pharmaceuticals
Erectile Dysfunction
Dornier Aries 2 Extracorporeal Shock Wave Device for the Treatment of Mild Erectile Dysfunction (ED)
This protocol allows for treatment of 100 men in two groups (placebo and active treatment) of 22-70 years of age with mild (IIEF EF of 17 to 25 at baseline) vasculogenic erectile dysfunction of at least 6 months duration with low…
- Trial name
- NCT03039218
- Testing
- Dornier Aries 2
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Dornier MedTech Systems
Dyslipidemia, Kidney Disease
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
The objective of this study is to evaluate the safety and efficacy of the combination of ABT-335 plus rosuvastatin in dyslipidemic subjects with Chronic Kidney Disease (CKD) Stage 3.
- Trial name
- NCT00680017
- Testing
- ABT-335 plus rosuvastatin, Rosuvastatin
- Where
- 114 sites in United States, Puerto Rico
- Volunteers
- 280 people
- Sponsor
- AstraZeneca
Preterm Labor, PreTerm Birth
Electrical Inhibition of Human Preterm Contractions
The purpose of this study is to explore a new method to stop preterm uterine contractions using an electrical device. The device, an "electrical pacemaker for the uterus," has been approved by the Food and Drug Administration…
- Conditions
- Preterm Labor, PreTerm Birth, Preterm Labor With Delivery Nos
- Trial name
- NCT02983240
- Testing
- Electrical Uterine Pacemaker
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- e-Bio Corp
Infections, Papillomavirus
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV…
- Trial name
- NCT00937950
- Testing
- Gynaecological follow-up
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 2,022 people
- Sponsor
- GlaxoSmithKline
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Overactive Bladder
Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects
The goal of this interventional clinical trial is to assess the safety, usability and initial efficacy of Xeomin and Vibe combination (ViXe) compared to placebo + sham in female subjects with idiopathic Overactive Bladder.
- Trial name
- XAVIER (NCT06345677)
- Testing
- ViXe Xombination
- Where
- 8 sites in Portugal
- Volunteers
- 48 people
- Sponsor
- Vensica Therapeutics Ltd.
Endometrial Neoplasms, Ovarian Cancer
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with…
- Conditions
- Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
- Trial name
- NCT04570839
- Testing
- COM701 in combination with BMS-986207 and nivolumab.
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Compugen Ltd
Cerebral Hemorrhage, Head Injury
Biomarkers Correlation With Volemia
The purpose of this study is to determine whether the Biomarkers (pro adrenomedullin (MR proADM), pro arginin vasopressin (CT proAVP), pro atrial natriuretic peptid (MR proANP), Pro Endothelin) changes at Day 2, Day 5 and Day 7…
- Conditions
- Cerebral Hemorrhage, Head Injury, Non Traumatic Post Surgery, Poly Trauma Patients Without Heart Failure
- Trial name
- ENVOL (NCT01858675)
- Testing
- Biomarkers, red blood cells and plasma assessment
- Where
- France
- Volunteers
- 66 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.